Is Arvinas, Inc. (ARVN) a Buy, Sell, or Hold?
Arvinas, Inc.
NASDAQ:ARVN
$8.27 USD
$0.17 (2.1%)
- Volume
- 636.79K
- Average Volume
- 837.54K
- Market Capitalization
- $533.59M
- P/E Ratio
- -2.54
- Dividend Yield
- 0.00%
- Price Target
- $14.50
- Year High
- $14.51
- Year Low
- $6.06
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.44
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Randy Teel |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ARVN |
| CUSIP | 04335A105 |
| CIK | 0001655759 |
| Web | https://www.arvinas.com |
| Phone | 203 535 1456 |
| Currency | USD |
| Employees | 246 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.44 |
| Quick Ratio | 5.44 |
| Cash Ratio | 0.75 |
Sales & Book Value
| Annual Sales | $262.6M |
| Price / Sales | 5.97 |
| Cash Flow | -4.01 |
| Price / Cash Flow | -2.08 |
| Price / Book | 1.37 |
Price Target and Rating
| Average Stock Price Forecast | $14.50 |
| High Stock Price Forecast | $20.00 |
| Low Stock Price Forecast | $10.00 |
| Forecast Upside/Downside | -42.97% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 26 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.28 |
| Trailing P/E Ratio | -2.54 |
| PEG Ratio | 0.02 |
| P/E Growth | 0.02 |
| Net Income | $-80.8M |
| Net Margin | -247.54% |
| Pretax Margin | -247.20% |
| Return on Equity | -44.39% |
| Return on Assets | -34.18% |
Financials Score
| AltmanZ Score | -2.44 |
| Piotroski Score | 3.00 |
| Working Capital | 514.8M |
| Total Assets | 647.5M |
| Ebit | -221M |
| Market Cap | 522.62M |
| Total Liabilities | 260.7M |
Poll Results
About Arvinas, Inc. (NASDAQ:ARVN) Stock
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degra ... der also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
2026-06-05 12:10:59
Arvinas NASDAQ: ARVN management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that may require broader development resources.
Arvinas to Present at Jefferies Global Healthcare Conference
2026-05-29 16:01:00
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET.
Arvinas to Present at Jefferies Global Healthcare Conference
2026-05-29 16:01:00
NEW HAVEN, Conn. , May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.
Arvinas Employees Give Back During Company-wide Impact Day
2026-05-18 10:30:00
NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that employees across Connecticut, in the Greater Boston area, and around the country, took part in the Company's fourth Arvinas Impact Day this past Friday. This company-wide day of service brings employees together to give back to their communities through volunteer activities that will make a meaningful difference across the Greater New Haven area and beyond.
These Analysts Increase Their Forecasts On Arvinas After Q1 Results
2026-05-13 13:54:35
Arvinas Inc (NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday.
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
2026-05-12 15:50:46
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
2026-05-12 14:38:28
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) for its oral PROTAC drug, VEPPANU (vepdegestrant).
Arvinas Q1 Earnings Call Highlights
2026-05-12 10:10:46
Arvinas NASDAQ: ARVN said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation.
Frequently Asked Questions
-
What is the current Arvinas, Inc. (ARVN) stock price?
-
Arvinas, Inc.(NASDAQ:ARVN) stock price is $8.27 in the last trading session. During the trading session, ARVN stock reached the peak price of $14.51 while $6.06 was the lowest point it dropped to. The percentage change in ARVN stock occurred in the recent session was 2.1% while the dollar amount for the price change in ARVN stock was $0.17.
-
ARVN's industry and sector of operation?
-
The NASDAQ listed ARVN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ARVN?
-
Andrew Saik | Chief Financial Officer & Treasurer
Jared Freedberg | General Counsel & Corporate Secretary
Noah Berkowitz | Chief Medical Officer
Randy Teel | CEO, President & Director
Alexander A. Santini | Chief Commercial Officer -
How many employees does ARVN have?
-
Number of ARVN employees currently stands at 246. ARVN operates from 5 Science Park, New Haven, CT 06511, US.
-
Link for ARVN official website?
-
Official Website of ARVN is: https://www.arvinas.com
-
How do I contact ARVN?
-
ARVN could be contacted at phone #203 535 1456 and can also be accessed through its website. ARVN operates from 5 Science Park, New Haven, CT 06511, US.
-
How many shares of ARVN are traded daily?
-
The average number of ARVN shares traded daily for last 3 months was 837.54K.
-
What is the market cap of ARVN currently?
-
The market value of ARVN currently stands at $533.59M with its latest stock price at $8.27